HYPERPHOSPHAT EMIA Group 5. Outlines -Disease manifestation (symptoms,signs), pathogenesis and pathophysiology. -Plan of treatment -Brief detail on pharmacology.

Slides:



Advertisements
Similar presentations
MINERAL AND BONE DISORDERS IN CHRONIC KIDNEY DISEASE PEDRAM.AHMADPOOR SHAHID BEHESHTI MEDICAL UNIVERSITY.
Advertisements

Antacids & Acid-Controlling Agents
Uncontrolled secondary hyperparathyroidism in a haemodialysis patient Jordi Bover, MD, PhD Fundació Puigvert Barcelona, Spain © Springer Healthcare, a.
End Stage Renal Disease in Children. End stage kidney disease occurs when the kidneys are no longer able to function at a level that is necessary for.
West Midlands Guidelines for managing CKD Mineral and Bone Disorders in Haemodialysis Patients
Calcium & phosphor disturbance CKD- MBD Dr. Atapour.
Management of hyperphosphataemia of chronic kidny disease Presented by Pharmacist/ Eman Youssif 1.
Agents Used in the Treatment of Hyperlipidemia
Hyperparathyroidism in Chronic Kidney Disease 醫五 李政霆.
Anemia in chronic kidney disease
Acid- Base Pathophysiology
Pharmacotherapy in the Elderly Paola S. Timiras May, 2007.
Pharmacotherapy in the Elderly Judy Wong
Dr. Sarah Zahid PHARMACOLOGICAL MANAGEMENT OF IRON DEFICIENCY ANEMIA.
Calcium Disorders Dr. Sohail Inam Consultant Endocrine & Diabetes Prince Sultan Military Medical City Riyadh.
Phosphate Binders … Not Just for Breakfast Anymore by Aimee Henry, DTR Sodexo Dietetic Intern.
CALCIUM HOMEOSTASIS Dr. Sumbul Fatma. Calcium Homeostasis Falling.
Pharmacology of drugs used in calcium & vitamin D disorders
Agents Used to Treat Hyperlipidemia. Hyperlipidemia 2 Atherosclerosis – accumulation of fatty substances on the inner wall of large and medium sized arteries.
oral hypoglycemic agents
Peritoneal Dialysis End Stage Renal Disease Causes and Treatment Methods.
Secondary Hyperparathyroidism in Chronic Kidney Disease 2009/11/13 신장내과 R3 이완수.
VANESSA WICKHAM AND NEIL BARRY
Dr. Sadia Batool Shahid PGT-M-Phil, Pharmacology
Chapter 19 Agents Used to Treat Hyperlipidemia. Hyperlipidemia 2 Atherosclerosis – accumulation of fatty substances on the inner wall of large and medium.
Chronic Kidney Disease SERVICE 6. Chronic Kidney Disease Stages 4-5 (GFR
Renal Osteodystrophy ( paraclinical evaluation ) Dr. Y. Ataipour Hashemi Nejad Hospital TUMS.
AGENTS USED FOR IRON DEFICIENCY
Clinical Pharmacokinetics of PHENYTOIN & OTHER ANTIEPILEPTICS
Chapter 21 Agents Used in the Treatment of Hyperlipidemia.
Drugs Used to Treat Dyslipidemias Chapter 22 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Hyperphosphataemia in chronic kidney disease Support for education and learning for children and young people’s renal services: slide set March 2013 NICE.
Hypocalcemia and Hypercalcemia
Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.
AGENTS FOR BONE AND BONE GROWTH : CALCIUM PREPARATIONS.
AGENTS FOR BONE AND BONE GROWTH : CALCIUM PREPARATIONS.
Electrolyte Emergencies
Parathyroid Gland & Calcium Metabolism
CKD Treatment 순천향 대학교병원 신장내과 R3 김재연. Chronic kidney disease (CKD) encompasses a spectrum of different pathophysiologic processes associated with abnormal.
Rayaldee® - calcifediol
Dietary restriction inadequate, phosphate still high Calcichew®
Oral Phosphate Binders in Patients with Kidney Failure
Chronic renal failure It is defined as either kidney damage or a decreased kidney glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m2 for 3.
MLAB 2401: Clinical Chemistry Keri Brophy-Martinez
Focus on Pharmacology Essentials for Health Professionals
Parathyroid Gland & Calcium Metabolism
Salmon Calcitonin Drugbank ID : DB00017
Factors Affecting Drug Activity
Chronic Renal Failure (End Stage Renal Disease “ESRD”)
Anticonvulsants: Valproic acid
Chapter 9 Clinical: Food-Drug Interactions
Antiuricaemic drugs Dr A.W Olusanya.
Diseases of the Renal System
Drugs for Hyperlipidemias
Metronidazole By Rajesh Patel.
Chronic kidney disease and pre-dialysis
Mucosal protective agents
Pharmacokinetics & Drug Dosing
Bone metabolism and disease in chronic kidney disease
oral hypoglycemic agents
Restless legs syndrome Wilson´s disease
Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials  Suetonia C. Palmer, PhD, Sharon Gardner, MA, Marcello Tonelli,
Volume 68, Pages S7-S14 (July 2005)
Barton Brezina, Wajeh Y. Qunibi, Charles R. Nolan  Kidney International 
Deprescribing Calcium-Based Phosphorus Binders in Dialysis Patients
Volume 66, Pages S25-S32 (September 2004)
Conclusion and Future Direction:
Diseases of the Renal System
Diseases of the Renal System
Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials  Suetonia C. Palmer, PhD, Sharon Gardner, MA, Marcello Tonelli,
Presentation transcript:

HYPERPHOSPHAT EMIA Group 5

Outlines -Disease manifestation (symptoms,signs), pathogenesis and pathophysiology. -Plan of treatment -Brief detail on pharmacology of the individual important drugs being used.

SIGN AND SYMPTOMS

Signs and symptoms Although most patients with hyperphosphatemia are asymptomatic, they occasionally report hypocalcemic symptoms. muscle cramps tetany perioral numbness or tingling. Othebone and joint pain, pruritus, and rash

PATHOGENESIS

Pathogenesis of hyperphosphatemia Vitamin D intoxication Decreased phosphate excretion because of renal failure

Normal of phosphate homeostas is

Vitamin D intoxicat ion

Decreased phosphate excretion because of renal failure

The Treatment concept of hyperphosphatemia in CKD and phosphate binders

Management of Hyperphosphatemia High phosphate diet restriction Medication: phosphate binders Dialysis intervention: HD or PD

Management of Hyperphosphatemia Limiting dietary phosphate intake: KDOQI : Dietary phosphorus restricted to 800 to 1,000 mg/day when The serum phosphorus levels are elevated (> 4.6 in CKD S3,4 or > 5.5 in CKD S5) The plasma levels of intact PTH are elevated above target range of the CKD stage \ American Journal of Kidney Diseases 2003;42(4):S12-S28.

Management of Hyperphosphatemia

If phosphorus or intact PTH level cannot be control with the target range, despite dietary phosphorus restriction, “Phosphate binders should be prescribed.”

Management of Hyperphosphatemia

Non calcium base binder Management of Hyperphosphatemia

Calcium-based

Calcium carbonate(500 mg,750 mg, 1000 mg) -40% elemental calcium -Dosage regimens: g (elemental calcium) three times daily with meals Mechanism of action Form Insoluble complex in intestines

Calcium acetate -25% calcium element -First-line agent: comparable efficacy to calcium carbonate with half the dose of elemental calcium

Adverse effects - Anorexia - constipation - Flatulence - Nausea - vomiting - Hypercalcemia

Management of Hyperphosphatemia

Non-calcium based phosphate binder

Mechanism of action Bind phosphate in the GI tract to form insoluble complexes and reduces phosphate absorption Aluminum hydroxide

Pharmacokinetics Insoluble, poorly absorbed Al salts in the intestines: hydroxides, Carbonated, phosphates and fatty acid derivatives, are excreted in feces Adverse effects Aluminium toxicity mainly three disorders: - aluminium-induced bone disease - microcytic anemia - neurological dysfunction (encephalopathy).

- Not a first-line agent Reserve for short-term use (4 wk) in patients with hyperphosphatemia not responding to other binders

Management of Hyperphosphatemia

Sevelamer carbonate/ Sevelamer hydrochloride

Mechanism of action Amines exist in a protonated form in the intestine and interact with phosphate molecules through ionic and hydrogen bonding Lower LDL-cholesterol

Pharmacokinetics -Not systemically absorbed -Elimination: Feces Adverse effect - vomiting (22%), nausea(20%), diarrhea (19%), dyspepsea (16%) Dosage tablet(400, 800mg), powder fororal suspension (800mg, 2,400 mg)

Lanthanum carbonate

Mechanism of action form strong complexes with Phosphate that inhibits GI absorption and results in a decrease of serum phosphate and calcium levels

Dosage and indication - Chewable tablet 500, 750, 1000 mg Pharmacokinetics -Half-life, elimination: 53 hr (plasma) -Peak plasma: 1 ng/ml -Bioavailability : 0.002% -Protein bound: 99% -Metabolism : not metabolized -Excretion : Predominantly feces Adverse effect: constipation, abdominal pain, diarrhea, hypertension

Comparison of Phosphate-binding agents

Indication as phosphate-binding agents Phosphate-binding properties Calcium carbonate Calcium citrate Aluminum hydroxide Sevelamer Lantanum

Administration Phosphate-binding properties Calcium carbonateTablets Calcium citrateTablets Aluminum hydroxideSuspension SevelamerPowder for suspension, tablets LantanumTablets

Efficacy

Advantages vs disadvantages

Management of Hyperphosphatemia

Take home message

Management of Hyperphosphatemia

Members 1.ChutinunSangkanjanavanich Thosapol Jeamanukoolkit PhongsathonThongkiew FeaungpongArunrodpanya PhitchakornTangaromsuk WichittraphonSukcharoen RattaratKengkoom TharitLee